MX2021009404A - Administracion del virus adenoasociado de polinucleotido de cln6. - Google Patents
Administracion del virus adenoasociado de polinucleotido de cln6.Info
- Publication number
- MX2021009404A MX2021009404A MX2021009404A MX2021009404A MX2021009404A MX 2021009404 A MX2021009404 A MX 2021009404A MX 2021009404 A MX2021009404 A MX 2021009404A MX 2021009404 A MX2021009404 A MX 2021009404A MX 2021009404 A MX2021009404 A MX 2021009404A
- Authority
- MX
- Mexico
- Prior art keywords
- cln6
- polynucleotide
- associated virus
- adeno
- raav
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a la administración del virus adenoasociado recombinante (rAAV) de un polinucleótido de lipofuscinosis ceroide neuronal 6 (CLN6). La divulgación proporciona el rAAV y métodos para utilizar el rAAV en el tratamiento génico de CLN6 de la lipofuscinosis ceroide neuronal o la enfermedad de Batten CLN6.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962800915P | 2019-02-04 | 2019-02-04 | |
US201962880641P | 2019-07-30 | 2019-07-30 | |
US201962881151P | 2019-07-31 | 2019-07-31 | |
US201962912977P | 2019-10-09 | 2019-10-09 | |
US201962923125P | 2019-10-18 | 2019-10-18 | |
PCT/US2020/016541 WO2020163299A1 (en) | 2019-02-04 | 2020-02-04 | Adeno-associated virus delivery of cln6 polynucleotide |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009404A true MX2021009404A (es) | 2021-11-12 |
Family
ID=69771088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009404A MX2021009404A (es) | 2019-02-04 | 2020-02-04 | Administracion del virus adenoasociado de polinucleotido de cln6. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220202956A1 (es) |
EP (1) | EP3921429A1 (es) |
JP (1) | JP2022519597A (es) |
KR (1) | KR20210124299A (es) |
CN (1) | CN113574176A (es) |
AU (1) | AU2020218501A1 (es) |
BR (1) | BR112021015150A2 (es) |
CA (1) | CA3127801A1 (es) |
CL (1) | CL2021002051A1 (es) |
IL (1) | IL285329A (es) |
MX (1) | MX2021009404A (es) |
SG (1) | SG11202107983TA (es) |
TW (1) | TW202033768A (es) |
WO (1) | WO2020163299A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150252384A1 (en) | 2012-08-01 | 2015-09-10 | National Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
WO2023018674A1 (en) * | 2021-08-09 | 2023-02-16 | Amicus Therapeutics, Inc. | Determination of gene transduction potency in neuron-like cells |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
JP3952312B2 (ja) | 1993-11-09 | 2007-08-01 | メディカル カレッジ オブ オハイオ | アデノ関連ウイルス複製遺伝子を発現可能な安定な細胞株 |
WO1995013365A1 (en) | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
CA2625279A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
AU715543B2 (en) | 1995-09-08 | 2000-02-03 | Genzyme Corporation | Improved AAV vectors for gene therapy |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
EP0932418B1 (en) | 1996-09-06 | 2007-12-05 | The Trustees Of The University Of Pennsylvania | Method for recombinant adeno-associated virus-directed gene therapy |
CA2830694C (en) | 1997-09-05 | 2018-02-27 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
CA2406743A1 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
JP6202701B2 (ja) | 2014-03-21 | 2017-09-27 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及びプログラム |
JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
WO2016100575A1 (en) * | 2014-12-16 | 2016-06-23 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
WO2017136536A1 (en) * | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
HRP20231451T1 (hr) * | 2016-02-05 | 2024-03-01 | Emory University | Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu |
-
2020
- 2020-02-04 KR KR1020217027481A patent/KR20210124299A/ko active Search and Examination
- 2020-02-04 SG SG11202107983TA patent/SG11202107983TA/en unknown
- 2020-02-04 WO PCT/US2020/016541 patent/WO2020163299A1/en unknown
- 2020-02-04 MX MX2021009404A patent/MX2021009404A/es unknown
- 2020-02-04 US US17/426,993 patent/US20220202956A1/en active Pending
- 2020-02-04 JP JP2021545402A patent/JP2022519597A/ja active Pending
- 2020-02-04 CN CN202080012159.9A patent/CN113574176A/zh active Pending
- 2020-02-04 TW TW109103421A patent/TW202033768A/zh unknown
- 2020-02-04 BR BR112021015150-8A patent/BR112021015150A2/pt unknown
- 2020-02-04 EP EP20709849.2A patent/EP3921429A1/en active Pending
- 2020-02-04 AU AU2020218501A patent/AU2020218501A1/en active Pending
- 2020-02-04 CA CA3127801A patent/CA3127801A1/en active Pending
-
2021
- 2021-08-03 CL CL2021002051A patent/CL2021002051A1/es unknown
- 2021-08-03 IL IL285329A patent/IL285329A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3127801A1 (en) | 2020-08-13 |
JP2022519597A (ja) | 2022-03-24 |
CL2021002051A1 (es) | 2022-04-08 |
AU2020218501A1 (en) | 2021-08-19 |
EP3921429A1 (en) | 2021-12-15 |
IL285329A (en) | 2021-09-30 |
SG11202107983TA (en) | 2021-08-30 |
US20220202956A1 (en) | 2022-06-30 |
BR112021015150A2 (pt) | 2021-09-28 |
CN113574176A (zh) | 2021-10-29 |
KR20210124299A (ko) | 2021-10-14 |
TW202033768A (zh) | 2020-09-16 |
WO2020163299A1 (en) | 2020-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009401A (es) | Administracion de virus adenoasociado de polinucleotido de cln3. | |
MX2019007873A (es) | Terapia génica para tratar la enfermedad de wilson. | |
AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
EP4001277A3 (en) | Bicyclic compounds for diagnosis and therapy | |
MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
MX2019010949A (es) | Moduladores de somatostatina y usos de los mismos. | |
MX2017014204A (es) | Formulaciones de tpp1 y metodos para tratar la enfemedad de cln2. | |
MX2022001874A (es) | Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos. | |
MX2021009404A (es) | Administracion del virus adenoasociado de polinucleotido de cln6. | |
EP3880823A4 (en) | THERAPEUTIC ADENO-ASSOCIATED VIRUS FOR THE TREATMENT OF PUMP DISEASE | |
WO2017070647A8 (en) | Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) | |
MX2020007586A (es) | Proceso de fabricacion de moduladores de somatostatina. | |
PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
PH12021550872A1 (en) | Therapeutic compounds | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
WO2020072451A8 (en) | Gene therapy for treating propionic acidemia | |
MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2019015741A (es) | Tratamiento con plasminogeno de afecciones asociadas a la sobreexpresion de pai-1. | |
BR112021021826A8 (pt) | Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4 | |
PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
EP3922264A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES | |
BR112016017478A2 (pt) | novos tratamentos | |
MX2021014789A (es) | Vectores aav con el promotor de la proteina cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las celulas de schwann como la enfermedad de charcot-marie-tooth. | |
MX2021008941A (es) | Moduladores gpr35. | |
MX2021004860A (es) | Piridazinas novedosas. |